Eribulin/farletuzumab antibody drug conjugate - Morphotek

Drug Profile

Eribulin/farletuzumab antibody drug conjugate - Morphotek

Alternative Names: Farletuzumab/eribulin ADC; MORAb-202

Latest Information Update: 26 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Morphotek
  • Class Antineoplastics; Drug conjugates; Immunoconjugates
  • Mechanism of Action Apoptosis stimulants; Cadherin modulators; Folate receptor 1 antagonists; Receptor protein-tyrosine kinase modulators; Tubulin polymerisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 19 Sep 2017 Preclinical trials in Cancer in USA before September 2017 (Parenteral)
  • 19 Sep 2017 Morphotek plans a clinical trial in Cancer in second half of 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top